应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00809 大成生化科技
已收盘 05-13 15:59:24
0.060
+0.002
+3.45%
最高
0.062
最低
0.057
成交量
558.00万
今开
0.057
昨收
0.058
日振幅
8.62%
总市值
10.07亿
流通市值
10.07亿
总股本
167.88亿
成交额
32.75万
换手率
0.03%
流通股本
167.88亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
大成生化科技(00809)附属就生产辅酶Q10菌丝体与神舟生物科技订立合作协议
智通财经 · 05-08
大成生化科技(00809)附属就生产辅酶Q10菌丝体与神舟生物科技订立合作协议
大成生化科技子公司与神州生物科技就辅酶Q10菌丝体达成合作协议
美股速递 · 05-08
大成生化科技子公司与神州生物科技就辅酶Q10菌丝体达成合作协议
大成生化科技更新2026年4月股份变动月报表,股本维持稳定
公告速递 · 05-04
大成生化科技更新2026年4月股份变动月报表,股本维持稳定
大成生化科技:2025年净利润1.56亿港元
南方财经网 · 04-24
大成生化科技:2025年净利润1.56亿港元
大成生化科技授予董事股份购回授权,规模达已发行股本一成
公告速递 · 04-24
大成生化科技授予董事股份购回授权,规模达已发行股本一成
大成生化科技2025年度收入攀升与结构优化并行,氨基酸业务承压净利润显著回落
公告速递 · 04-24
大成生化科技2025年度收入攀升与结构优化并行,氨基酸业务承压净利润显著回落
大成生化科技2026年3月股份变动月报表,股本维持不变
公告速递 · 04-01
大成生化科技2026年3月股份变动月报表,股本维持不变
大成生化科技(00809)发布年度业绩,年度溢利1.56亿港元 同比减少79.69%
智通财经 · 03-28
大成生化科技(00809)发布年度业绩,年度溢利1.56亿港元 同比减少79.69%
大成生化科技(00809)拟“10合1”进行股份合并及更改每手买卖单位
智通财经 · 03-27
大成生化科技(00809)拟“10合1”进行股份合并及更改每手买卖单位
大成生化科技拟“10合1”股份合并并将每手买卖单位调至1万股
公告速递 · 03-27
大成生化科技拟“10合1”股份合并并将每手买卖单位调至1万股
大成生化科技(00809)发盈警 预期2025年净收益约1亿港元至3亿港元
智通财经 · 03-18
大成生化科技(00809)发盈警 预期2025年净收益约1亿港元至3亿港元
大成生化科技(00809):预计2025年度净收益同比下降59.8%至86.6%
公告速递 · 03-18
大成生化科技(00809):预计2025年度净收益同比下降59.8%至86.6%
大成生化科技盘中异动 下午盘股价大涨5.08%
市场透视 · 03-04
大成生化科技盘中异动 下午盘股价大涨5.08%
大成生化科技(00809)披露2026年2月股份变动月报:股本结构保持不变
公告速递 · 03-02
大成生化科技(00809)披露2026年2月股份变动月报:股本结构保持不变
大成生化科技盘中异动 下午盘急速上涨5.00%报0.063港元
市场透视 · 02-12
大成生化科技盘中异动 下午盘急速上涨5.00%报0.063港元
大成生化科技盘中异动 临近收盘快速上涨5.00%
市场透视 · 02-03
大成生化科技盘中异动 临近收盘快速上涨5.00%
大成生化科技02月02日主力净流出29.1万元 散户资金买入
市场透视 · 02-02
大成生化科技02月02日主力净流出29.1万元 散户资金买入
大成生化科技盘中异动 股价大跌10.29%报0.061港元
市场透视 · 01-19
大成生化科技盘中异动 股价大跌10.29%报0.061港元
大成生化科技盘中异动 下午盘股价大跌5.97%
市场透视 · 01-07
大成生化科技盘中异动 下午盘股价大跌5.97%
大成生化(00809)2025年12月股份变动月报:股本保持稳定
公告速递 · 01-02
大成生化(00809)2025年12月股份变动月报:股本保持稳定
暂无数据
公司概况
公司名称:
大成生化科技
所属市场:
SEHK
上市日期:
--
主营业务:
大成生化科技集团有限公司是一家主要从事赖氨酸及苏氨酸等生化产品制造及销售业务的投资控股公司。该公司通过四大分部运营业务。氨基酸分部从事赖氨酸及苏氨酸等以玉米为原料的氨基酸产品的生产及销售业务。上游产品分部从事玉米淀粉、玉米蛋白粉、玉米油及其他玉米提炼产品的生产及销售业务。玉米甜味剂分部从事葡萄糖浆、麦芽糖浆、高果糖浆、结晶葡萄糖及麦芽糊精等以玉米为原料的甜味剂产品的生产及销售业务。生物化工醇分部从事生物化工醇、溶雪产品、氢气及液氨等以玉米为原料的生化产品的生产及销售业务。
发行价格:
--
{"stockData":{"symbol":"00809","market":"HK","secType":"STK","nameCN":"大成生化科技","latestPrice":0.06,"timestamp":1778659164229,"preClose":0.058,"halted":0,"volume":5580000,"delay":0,"changeRate":0.034482758620689564,"floatShares":16788000000,"shares":16788000000,"eps":0.006,"marketStatus":"已收盘","change":0.002,"latestTime":"05-13 15:59:24","open":0.057,"high":0.062,"low":0.057,"amount":327522,"amplitude":0.086207,"askPrice":0.061,"askSize":150000,"bidPrice":0.06,"bidSize":7146000,"shortable":0,"etf":0,"ttmEps":0.009,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778722200000},"marketStatusCode":5,"adr":0,"listingDate":984672000000,"exchange":"SEHK","adjPreClose":0.058,"openAndCloseTimeList":[[1778635800000,1778644800000],[1778648400000,1778659200000]],"volumeRatio":1.479635,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00809/tweets","defaultTab":"tweets","newsList":[{"id":"2633391434","title":"大成生化科技(00809)附属就生产辅酶Q10菌丝体与神舟生物科技订立合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2633391434","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633391434?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:26","pubTimestamp":1778232395,"startTime":"0","endTime":"0","summary":"智通财经APP讯,大成生化科技 发布公告,本公司间接全资附属公司长春大成大合生物技术开发有限公司与神舟生物科技有限责任公司订立合作协议,据此,神舟生物科技同意委聘大成大合生产辅酶Q10菌丝体。双方亦协定,在神舟生物科技对产品检验合格后,神舟生物科技将根据其月度采购计划向大成大合采购辅酶Q10菌丝体,于2027年1月1日至2028年12月31日期间的最低采购量为1270公吨辅酶Q10。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","00809","BK4585","BK1212","159837","HBImain","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160001767","title":"大成生化科技子公司与神州生物科技就辅酶Q10菌丝体达成合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1160001767","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160001767?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:24","pubTimestamp":1778232299,"startTime":"0","endTime":"0","summary":"大成生化科技集团有限公司宣布,其旗下子公司已与神州生物科技正式签署合作协议,双方将围绕辅酶Q10菌丝体的研发与生产展开深度协作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1212","00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151195325","title":"大成生化科技更新2026年4月股份变动月报表,股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1151195325","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151195325?lang=zh_cn&edition=full","pubTime":"2026-05-04 17:32","pubTimestamp":1777887170,"startTime":"0","endTime":"0","summary":"大成生化科技于2026年5月4日发布了截至2026年4月30日的股份变动月报表。根据公告,公司本月股本结构和已发行股份总数均未发生变动。大成生化科技本月普通股法定股本维持30,000,000,000股,面值每股0.1港元,金额合计3,000,000,000港元;可换股优先股法定股本同样保持30,000,000,000股,金额合计3,000,000,000港元,合并后法定股本总额仍为6,000,000,000港元。大成生化科技在公告中确认,所有股份事项均遵守香港联合交易所有限公司《上市规则》及相关法规要求。本次公告由公司秘书陈昇辉签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629643698","title":"大成生化科技:2025年净利润1.56亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629643698","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629643698?lang=zh_cn&edition=full","pubTime":"2026-04-24 07:07","pubTimestamp":1776985620,"startTime":"0","endTime":"0","summary":"南财智讯4月24日电,大成生化科技(00809.HK)公告,截至2025年12月31日止年度,公司年内溢利为1.56亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604243716840534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147931096","title":"大成生化科技授予董事股份购回授权,规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1147931096","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147931096?lang=zh_cn&edition=full","pubTime":"2026-04-24 06:55","pubTimestamp":1776984948,"startTime":"0","endTime":"0","summary":"大成生化科技公告称,其董事会已获授一般及无条件授权,可在联交所或其他合规市场购回最多相当于公司已发行股本总数10%的股份。截至公告日,公司已发行股份数为16,788,211,527股,如回购上限全部执行,规模最多可达1,678,821,152股。根据公告,董事会表示,公司回购股份所需资金将来自合法财务来源,依据开曼群岛公司法及相关上市规则安排,可使用公司利润或股票溢价账户等渠道进行。过往股价数据显示,大成生化科技近期股价区间约为每股0.06港元至0.122港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"大成生化科技授予董事股份购回授权,规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134725284","title":"大成生化科技2025年度收入攀升与结构优化并行,氨基酸业务承压净利润显著回落","url":"https://stock-news.laohu8.com/highlight/detail?id=1134725284","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134725284?lang=zh_cn&edition=full","pubTime":"2026-04-24 06:53","pubTimestamp":1776984806,"startTime":"0","endTime":"0","summary":"大成生化科技于本报告期实现收入约22.79亿港元,较2024年的20.01亿港元增长13.9%,主要源于玉米浆糖、氨基酸及玉米淀粉深加工等板块的整体扩张。氨基酸及其相关产品仍为集团核心业务,年内录得约19.44亿港元销售收入,受国际需求、原材料成本及渠道布局变化影响,毛利率由2024年的9.5%降至2025年的8.6%。公司未来战略重点仍围绕提升核心氨基酸业务及产能恢复推进,同时兼顾锅炉翻修、超高温蒸煮、生物燃料等在研或在建项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"大成生化科技2025年度收入攀升与结构优化并行,氨基酸业务承压净利润显著回落","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198324002","title":"大成生化科技2026年3月股份变动月报表,股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1198324002","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198324002?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:40","pubTimestamp":1775032813,"startTime":"0","endTime":"0","summary":"大成生化科技集团有限公司于2026年4月1日披露2026年3月股份变动月报表。报告期截至2026年3月31日,公司各类股份数量及注册股本均未发生变化。大成生化科技集团有限公司本月底法定注册股本总额仍为港币6,000,000,000。普通股方面,在2026年3月底公司已发行16,788,211,527股,另有44,560,000股作为库藏股,总计16,832,771,527股;优先股已发行数量维持在17,267,750,569股,报告期内未有新增发行、回购或注销。公告显示,截至本月末,公司股本总数保持不变。公告由公司秘书陈昇辉签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622879189","title":"大成生化科技(00809)发布年度业绩,年度溢利1.56亿港元 同比减少79.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622879189","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622879189?lang=zh_cn&edition=full","pubTime":"2026-03-28 00:33","pubTimestamp":1774629228,"startTime":"0","endTime":"0","summary":"智通财经APP讯,大成生化科技 发布截至2025年12月31日止年度业绩,该集团取得收益22.79亿港元,同比增加13.86%;本年度溢利1.56亿港元,同比减少79.69%;每股基本盈利1.4港仙。因此,本地供应商倾向将氨基酸产品转售至国内市场,而为应对中国氨基酸产品供应过剩,集团已于2025年第四季度调整氨基酸产量,以达致最佳生产开工率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"大成生化科技(00809)发布年度业绩,年度溢利1.56亿港元 同比减少79.69%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1212","00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622873109","title":"大成生化科技(00809)拟“10合1”进行股份合并及更改每手买卖单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2622873109","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622873109?lang=zh_cn&edition=full","pubTime":"2026-03-27 23:00","pubTimestamp":1774623638,"startTime":"0","endTime":"0","summary":"智通财经APP讯,大成生化科技(00809)发布公告,董事会建议实施股份合并,基准为(i)每10股每股面值0.10港元的已发行及未发行现有股份将合并为1股每股面值1.00港元的合并股份;(ii)每10股每股面值0.10港元的已发行及未发行现有可换股优先股将合并为1股每股面值1.00港元的合并可换股优先股。于本公告日期,现有股份以每手买卖单位2000股现有股份在联交所买卖。受限于及待股份合并生效后,建议将在联交所买卖的每手买卖单位由2000股现有股份更改为1万股合并股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00809","BK1212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171186152","title":"大成生化科技拟“10合1”股份合并并将每手买卖单位调至1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1171186152","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171186152?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:17","pubTimestamp":1774621046,"startTime":"0","endTime":"0","summary":"大成生化科技3月27日晚间公告,董事会建议实施股份合并及调整每手买卖单位,相关议案将提交拟于2026年6月24日举行的股东周年大会审议。受限于并待股份合并生效,公司拟把港股市场的每手买卖单位由现行2,000股调整为10,000股合并股份。董事会预期,合并及调整每手买卖单位不会对集团财务状况、营运及股东权益造成重大不利影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620790252","title":"大成生化科技(00809)发盈警 预期2025年净收益约1亿港元至3亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620790252","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620790252?lang=zh_cn&edition=full","pubTime":"2026-03-18 22:42","pubTimestamp":1773844936,"startTime":"0","endTime":"0","summary":"然而,本年度毛利率预期与去年同期的9.5%相比,将降至8.6%。本年度毛利率及净收益预期下降主要归因于以下因素:自2025年年中起,国内玉米颗粒价格上涨导致本集团的经营成本增加;及欧洲联盟对中国内地赖氨酸发起反倾销调查引致国内市场赖氨酸产品供过于求,两者均对本集团的毛利率造成不利影响;及在2024年12月30日完成出售本公司八间附属公司后,未确认一次性收益约 19.62亿港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00809","BK1212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129856475","title":"大成生化科技(00809):预计2025年度净收益同比下降59.8%至86.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129856475","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129856475?lang=zh_cn&edition=full","pubTime":"2026-03-18 22:40","pubTimestamp":1773844845,"startTime":"0","endTime":"0","summary":"大成生化科技3月18日晚间发布盈利警告称,经对截至2025年12月31日止年度未经审核综合管理账目进行初步评估,预计本年度将录得净收益(税前)约1亿至3亿港元,较2024年度的7.456亿港元大幅下滑,降幅约59.8%至86.6%。\\n\\n营收和毛利方面,本年度收入预计约22.785亿港元,同比增长13.9%;毛利约1.964亿港元,同比增长2.8%。受成本端和售价端双重因素影响,毛利率预计由去年同期的9.5%降至8.6%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616535657","title":"大成生化科技盘中异动 下午盘股价大涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616535657","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616535657?lang=zh_cn&edition=full","pubTime":"2026-03-04 13:19","pubTimestamp":1772601588,"startTime":"0","endTime":"0","summary":"2026年03月04日下午盘13时19分,大成生化科技股票出现异动,股价急速拉升5.08%。截至发稿,该股报0.062港元/股,成交量125.2万股,换手率0.01%,振幅5.08%。大成生化科技股票所在的化肥农药行业中,整体跌幅为0.05%。其相关个股中,大成生化科技、米高集团、泰达生物涨幅较大,振幅较大的相关个股有玖源集团、中海石油化学、中化化肥,振幅分别为26.23%、6.37%、5.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304131948a6a09709&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304131948a6a09709&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00809","BK1212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169962612","title":"大成生化科技(00809)披露2026年2月股份变动月报:股本结构保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1169962612","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169962612?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:41","pubTimestamp":1772440917,"startTime":"0","endTime":"0","summary":"大成生化科技集团有限公司于2026年3月2日发布2026年2月股份变动月报,披露公司当月各类股份及注册股本情况。本次月报涵盖普通股与优先股的发行数量、已发行股份及库存股份情况等信息。截至2026年2月28日,法定注册股本总额为6,000,000,000港元,较上月无变化。本次月报由公司秘书陈昇辉签署。根据公告内容,截至2月底,公司股本总数与上月相比保持稳定,未有股份发行及回购活动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610785919","title":"大成生化科技盘中异动 下午盘急速上涨5.00%报0.063港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610785919","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610785919?lang=zh_cn&edition=full","pubTime":"2026-02-12 14:14","pubTimestamp":1770876840,"startTime":"0","endTime":"0","summary":"2026年02月12日下午盘14时14分,大成生化科技股票出现异动,股价大幅上涨5.00%。截至发稿,该股报0.063港元/股,成交量242.8万股,换手率0.01%,振幅5.00%。资金方面,该股资金流入13.7106万港元,流出1.2762万港元。大成生化科技股票所在的化肥农药行业中,整体涨幅为0.03%。其相关个股中,大成生化科技、中国心连心化肥、中海石油化学涨幅较大,振幅较大的相关个股有富一国际控股、中化化肥、大成生化科技,振幅分别为7.14%、4.14%、3.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212141400a49b1805&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212141400a49b1805&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1212","00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608374693","title":"大成生化科技盘中异动 临近收盘快速上涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608374693","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608374693?lang=zh_cn&edition=full","pubTime":"2026-02-03 15:38","pubTimestamp":1770104324,"startTime":"0","endTime":"0","summary":"2026年02月03日临近收盘15时38分,大成生化科技股票出现异动,股价快速上涨5.00%。截至发稿,该股报0.063港元/股,成交量316.8万股,换手率0.02%,振幅5.00%。大成生化科技股票所在的化肥农药行业中,整体涨幅为0.08%。其相关个股中,东光化工、大成生化科技、米高集团涨幅较大,振幅较大的相关个股有泰达生物、大成生化科技、中国心连心化肥,振幅分别为7.14%、5.00%、4.58%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203153845a4768226&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203153845a4768226&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1212","00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608893869","title":"大成生化科技02月02日主力净流出29.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2608893869","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608893869?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:16","pubTimestamp":1770020167,"startTime":"0","endTime":"0","summary":"02月02日, 大成生化科技股价跌10.45%,报收0.06元,成交金额186.8万元,换手率0.18%,振幅10.45%,量比8.87。大成生化科技今日主力资金净流出29.1万元,上一交易日主力净流出0万元。该股近5个交易日下跌11.76%,主力资金累计净流出29.1万元;近20日主力资金累计净流入13.4万元,其中净流入天数为1日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202162444a6c978a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202162444a6c978a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1212","00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604884154","title":"大成生化科技盘中异动 股价大跌10.29%报0.061港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604884154","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604884154?lang=zh_cn&edition=full","pubTime":"2026-01-19 10:45","pubTimestamp":1768790719,"startTime":"0","endTime":"0","summary":"2026年01月19日早盘10时45分,大成生化科技股票出现波动,股价快速下跌10.29%。截至发稿,该股报0.061港元/股,成交量584万股,换手率0.03%,振幅5.88%。大成生化科技股票所在的化肥农药行业中,整体涨幅为0.02%。其相关个股中,中国心连心化肥、泰达生物、中海石油化学涨幅较大,振幅较大的相关个股有大成生化科技、中国心连心化肥、泰达生物,振幅分别为5.88%、3.68%、3.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119104519953d461d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119104519953d461d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00809","BK1212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601808947","title":"大成生化科技盘中异动 下午盘股价大跌5.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601808947","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601808947?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:11","pubTimestamp":1767769919,"startTime":"0","endTime":"0","summary":"2026年01月07日下午盘15时11分,大成生化科技股票出现异动,股价大幅下挫5.97%。截至发稿,该股报0.063港元/股,成交量767.6万股,换手率0.05%,振幅8.96%。大成生化科技股票所在的化肥农药行业中,整体跌幅为0.03%。其相关个股中,米高集团、中海石油化学、东光化工涨幅较大,振幅较大的相关个股有玖源集团、大成生化科技、米高集团,振幅分别为9.37%、8.96%、3.91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107151159953c22c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107151159953c22c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1212","00809"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141549660","title":"大成生化(00809)2025年12月股份变动月报:股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1141549660","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141549660?lang=zh_cn&edition=full","pubTime":"2026-01-02 17:01","pubTimestamp":1767344471,"startTime":"0","endTime":"0","summary":"大成生化科技集团有限公司于2026年1月2日发布截至2025年12月31日的股份变动月报表。公告显示,公司在报告期内并无新增发行、购回或注销事项,整体股本维持稳定。公司注册股本包括普通股与可换股优先股两类,普通股及可换股优先股分别拥有30,000,000,000股法定/注册股份,面值均为每股0.1港元,报告期末两类股份合计法定/注册股本总额为6,000,000,000港元。报告显示,公司并无在报告期内授出或行使新的股份期权及其他股权激励计划,也未有购回或注销信息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00809"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.globalbiochem.com","stockEarnings":[{"period":"1week","weight":-0.0169},{"period":"1month","weight":0},{"period":"3month","weight":-0.0333},{"period":"6month","weight":-0.3012},{"period":"1year","weight":-0.1471},{"period":"ytd","weight":-0.1077}],"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0175},{"period":"3month","weight":-0.0337},{"period":"6month","weight":-0.0268},{"period":"1year","weight":0.1188},{"period":"ytd","weight":0.028}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"大成生化科技集团有限公司是一家主要从事赖氨酸及苏氨酸等生化产品制造及销售业务的投资控股公司。该公司通过四大分部运营业务。氨基酸分部从事赖氨酸及苏氨酸等以玉米为原料的氨基酸产品的生产及销售业务。上游产品分部从事玉米淀粉、玉米蛋白粉、玉米油及其他玉米提炼产品的生产及销售业务。玉米甜味剂分部从事葡萄糖浆、麦芽糖浆、高果糖浆、结晶葡萄糖及麦芽糊精等以玉米为原料的甜味剂产品的生产及销售业务。生物化工醇分部从事生物化工醇、溶雪产品、氢气及液氨等以玉米为原料的生化产品的生产及销售业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.48,"avgChangeRate":-0.004673},{"month":2,"riseRate":0.32,"avgChangeRate":0.008933},{"month":3,"riseRate":0.36,"avgChangeRate":-0.017864},{"month":4,"riseRate":0.5,"avgChangeRate":0.088084},{"month":5,"riseRate":0.52,"avgChangeRate":0.056377},{"month":6,"riseRate":0.36,"avgChangeRate":-0.034229},{"month":7,"riseRate":0.44,"avgChangeRate":-0.007044},{"month":8,"riseRate":0.24,"avgChangeRate":-0.031},{"month":9,"riseRate":0.44,"avgChangeRate":0.002158},{"month":10,"riseRate":0.48,"avgChangeRate":-0.004313},{"month":11,"riseRate":0.4,"avgChangeRate":0.046529},{"month":12,"riseRate":0.44,"avgChangeRate":0.02394}],"exchange":"SEHK","name":"大成生化科技","nameEN":"GLOBAL BIO-CHEM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"大成生化科技(00809)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供大成生化科技(00809)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"大成生化科技,00809,大成生化科技股票,大成生化科技股票老虎,大成生化科技股票老虎国际,大成生化科技行情,大成生化科技股票行情,大成生化科技股价,大成生化科技股市,大成生化科技股票价格,大成生化科技股票交易,大成生化科技股票购买,大成生化科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"大成生化科技(00809)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供大成生化科技(00809)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}